|
FAM64A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66688884917221E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.3081536681957E-13 |
| Normal-vs-Stage2 |
1.256020E-03 |
| Normal-vs-Stage3 |
5.77430000037182E-07 |
| Normal-vs-Stage4 |
8.73330000539241E-08 |
| Stage1-vs-Stage2 |
4.843600E-02 |
| Stage1-vs-Stage3 |
6.115000E-01 |
| Stage1-vs-Stage4 |
5.222600E-01 |
| Stage2-vs-Stage3 |
4.399700E-02 |
| Stage2-vs-Stage4 |
2.568500E-02 |
| Stage3-vs-Stage4 |
9.405200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63902225125412E-12 |
| Normal-vs-AfricanAmerican |
9.811900E-04 |
| Normal-vs-Asian |
7.11149999998995E-07 |
| Caucasian-vs-AfricanAmerican |
2.834000E-01 |
| Caucasian-vs-Asian |
5.578400E-01 |
| AfricanAmerican-vs-Asian |
6.001400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.9959000008285E-08 |
| Normal-vs-Female |
1.99396055222678E-12 |
| Male-vs-Female |
3.818200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64390723256247E-12 |
| Normal-vs-Age(41-60Yrs) |
3.57800000738706E-09 |
| Normal-vs-Age(61-80Yrs) |
1.81649999997369E-06 |
| Normal-vs-Age(81-100Yrs) |
8.765800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.375550E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.444020E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.605200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.684800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.820620E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.057000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.604200E-01 |
| Classical-VS-Follicular |
5.437400E-04 |
| Classical-VS-Other |
8.311000E-01 |
| Classical-VS-Normal |
2.66453525910038E-15 |
| Tall-VS-Follicular |
1.982680E-03 |
| Tall-VS-Other |
4.368200E-01 |
| Tall-VS-Normal |
2.11959999996125E-07 |
| Follicular-VS-Other |
3.206200E-01 |
| Follicular-VS-Normal |
4.435200E-03 |
| Other-VS-Normal |
9.162000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.19070000526023E-08 |
| Normal-vs-N1 |
8.1344999958155E-08 |
| N0-vs-N1 |
4.995600E-01 |
|
|
